C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells

[1]  Leonard Moise,et al.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.

[2]  P. Sagoo,et al.  Expression of complement components, receptors and regulators by human dendritic cells , 2011, Molecular Immunology.

[3]  Leonard Moise,et al.  Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine , 2011, Immunome research.

[4]  D. Isenman,et al.  A Crystal Structure of the Complex Between Human Complement Receptor 2 and Its Ligand C3d , 2011, Science.

[5]  J. Forrester,et al.  Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis , 2010, European journal of immunology.

[6]  J. Ahearn,et al.  Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[7]  Anne S De Groot,et al.  Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.

[8]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[9]  H. Siljander,et al.  Autoimmune mechanisms in type 1 diabetes. , 2008, Autoimmunity reviews.

[10]  A. D. De Groot,et al.  Novel function of complement C3d as an autologous helper T cell target , 2008 .

[11]  A. D. De Groot,et al.  Novel function of complement C3d as an autologous helper T‐cell target , 2008, Immunology and cell biology.

[12]  Roland Martin,et al.  Multiple sclerosis: a complicated picture of autoimmunity , 2007, Nature Immunology.

[13]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[14]  William W. Kwok,et al.  Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.

[15]  Wuding Zhou,et al.  Dendritic Cell Synthesis of C3 Is Required for Full T Cell Activation and Development of a Th1 Phenotype1 , 2006, The Journal of Immunology.

[16]  N. Greenspan,et al.  Complement Component C3d-Antigen Complexes Can Either Augment or Inhibit B Lymphocyte Activation and Humoral Immunity in Mice Depending on the Degree of CD21/CD19 Complex Engagement1 , 2005, The Journal of Immunology.

[17]  Yong Hu,et al.  Role of Complement Receptor Type 2 and Endogenous Complement in the Humoral Immune Response to Conjugates of Complement C3d and Pneumococcal Serotype 14 Capsular Polysaccharide , 2005, Infection and Immunity.

[18]  B. Kyewski,et al.  Self-representation in the thymus: an extended view , 2004, Nature Reviews Immunology.

[19]  D. Karp,et al.  Cutting Edge: C3d Functions as a Molecular Adjuvant in the Absence of CD21/35 Expression 1 , 2004, The Journal of Immunology.

[20]  J. Sodroski,et al.  Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d , 2004, Journal of Virology.

[21]  I. Jónsdóttir,et al.  Mucosal Vaccination Against Encapsulated Respiratory Bacteria – New Potentials for Conjugate Vaccines? , 2003, Scandinavian journal of immunology.

[22]  M. Bachmann,et al.  Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection , 2002, Nature Medicine.

[23]  P. Geusens,et al.  The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. , 2001, Seminars in arthritis and rheumatism.

[24]  A. Lucas,et al.  Increased Immunogenicity and Induction of Class Switching by Conjugation of Complement C3d to Pneumococcal Serotype 14 Capsular Polysaccharide , 2001, Infection and Immunity.

[25]  P. Kourilsky,et al.  Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. , 2000, Immunity.

[26]  H. Kohler,et al.  Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide , 1998, Nature Biotechnology.

[27]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[28]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[29]  D. Kioussis,et al.  Low avidity recognition of self-antigen by T cells permits escape from central tolerance. , 1995, Immunity.

[30]  A. Ben-nun,et al.  Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)‐derived peptide: Preliminary analysis of MOG T cell epitopes , 1995, European journal of immunology.

[31]  R. Diefenbach,et al.  Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2. , 1995, Journal of immunology.

[32]  N. Cooper,et al.  Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. , 1994, Journal of immunology.

[33]  John D Lambris,et al.  C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. , 1989, Journal of immunology.

[34]  John D Lambris,et al.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Berzofsky,et al.  Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes , 2010 .

[36]  T. Ross,et al.  A minimum CR2 binding domain of C3d enhances immunity following vaccination. , 2006, Advances in experimental medicine and biology.

[37]  A. D. De Groot,et al.  Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. , 2003, Developments in biologicals.

[38]  J. Berzofsky,et al.  Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design , 2002 .

[39]  D. Fearon,et al.  Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. , 2000, Annual review of immunology.

[40]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .